Our top pick for
Building a portfolio
Freeline Therapeutics Holdings plc is a biotechnology business based in the US. Freeline Therapeutics shares (FRLN) are listed on the NASDAQ and all prices are listed in US Dollars. Freeline Therapeutics employs 236 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$11.85 - $21.69|
|50-day moving average||$13.67|
|200-day moving average||$16.03|
|Wall St. target price||$25.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$0|
|Return on assets TTM||-29.77%|
|Return on equity TTM||-57.55%|
|Market capitalisation||$445.2 million|
TTM: trailing 12 months
There are currently 29,491 Freeline Therapeutics shares held short by investors – that's known as Freeline Therapeutics's "short interest". This figure is 8.8% down from 32,354 last month.
There are a few different ways that this level of interest in shorting Freeline Therapeutics shares can be evaluated.
Freeline Therapeutics's "short interest ratio" (SIR) is the quantity of Freeline Therapeutics shares currently shorted divided by the average quantity of Freeline Therapeutics shares traded daily (recently around 11430.620155039). Freeline Therapeutics's SIR currently stands at 2.58. In other words for every 100,000 Freeline Therapeutics shares traded daily on the market, roughly 2580 shares are currently held short.
However Freeline Therapeutics's short interest can also be evaluated against the total number of Freeline Therapeutics shares, or, against the total number of tradable Freeline Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Freeline Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Freeline Therapeutics shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Freeline Therapeutics shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Freeline Therapeutics.
Find out more about how you can short Freeline Therapeutics stock.
We're not expecting Freeline Therapeutics to pay a dividend over the next 12 months.
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. .
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.